首页> 外文OA文献 >A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy

【2h】

A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy

机译：一种新颖的适应性试验设计：硼替佐米（REMODL-B）对弥散性大b细胞淋巴瘤分子指导治疗的随机评估，并进行两次中期分析以探讨安全性和有效性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy [J] . Tom Maishman, Louise Stanton, Andy Davies, Trials . 2013,第SUPPLEMENTa1期

机译：一种新颖的适应性试验设计：采用硼替佐米（REMODL-B）对弥散性大b细胞淋巴瘤进行分子指导治疗的随机评估，并进行两次中期分析以探讨安全性和有效性
2. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial [J] . Davies Andrew, Cummin Thomas E., Barrans Sharon, The lancet oncology . 2019,第5期

机译：Bortezomib的基因表达分析加入到标准化疗中的弥漫性大B细胞淋巴瘤（Remodl-B）：开放标签，随机，第3阶段试验
3. Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome [J] . Julia Richter, Andreas Hüttmann, Jan Rekowski, Blood cancer journal. . 2019,第9期

机译：散射大B细胞淋巴瘤在侵袭性非霍奇金淋巴瘤（PATEL）试验中的正电子发射断层扫描治疗中的分子特征：与临时宠物和结果相关
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy [O] . Tom Maishman, Louise Stanton, Andy Davies, 2013

机译：一种新颖的适应性试验设计：硼替佐米（REMODL-B）对弥散性大b细胞淋巴瘤分子指导治疗的随机评估并进行两次中期分析以探讨安全性和有效性
6. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial [O] . Andrew Davies, Thomas E Cummin, Sharon Barrans, 2019

机译：Bortezomib的基因表达分析加入到标准化疗瘤疗法中弥漫性大B细胞淋巴瘤（REMODL-B）：开放标签，随机，第3阶段试验

A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy

著录项

引文网络

相似文献

相关主题

期刊订阅